Form 4: Bolt Biotherapeutics Director Granted Stock Options Following Reverse Stock Split

Bolt Biotherapeutics Director Brian O'Callaghan was granted 1,100 stock options with an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Summary

• Reporting person Brian O'Callaghan, a Director of Bolt Biotherapeutics, Inc. (BOLT), acquired stock options.
• The options grant the right to buy 1,100 shares of common stock.
• The exercise price for these options is $6.4 per share.
• This transaction occurred on May 27, 2025.
• The reported share and exercise price amounts reflect a 1-for-20 reverse stock split effected by the company on June 6, 2025.
• Prior to the reverse stock split, the options were for 22,000 shares at an exercise price of $0.3200 per share.
• The options will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service.
• Full vesting will occur upon a change in control of the Issuer.
• The options expire on May 26, 2035.

Sentiment

Score: 7

Explanation: The filing is a routine Form 4 disclosing an insider's acquisition of stock options. While not indicative of new operational performance, the grant of options to a director is a positive for corporate governance as it aligns the director's interests with long-term shareholder value. The context of a reverse stock split is noted but the Form 4 itself is a standard disclosure.

Positives

• Grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The vesting schedule includes accelerated vesting upon a change in control, which could benefit the director in such an event.

Negatives

• No direct negatives are reported in this Form 4 filing, which primarily details an insider's stock option grant.

Risks

• No specific risks are detailed in this Form 4 filing, which is a disclosure of an insider transaction.

Future Outlook

The stock options are subject to a vesting schedule, with full vesting upon a change in control, aligning the director's future incentives with the company's performance and potential strategic events.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology industry, used to attract and retain talent and align executive interests with long-term shareholder value. The reverse stock split, while not directly part of this Form 4, is a broader corporate action often undertaken by biotech companies to meet listing requirements or improve stock perception.

Comparison to Industry Standards

• Equity compensation, such as stock options, is a standard component of executive and director compensation packages across the biotechnology sector, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen, which frequently use such incentives to align leadership with company performance.
• The specific terms, including exercise price and vesting schedule, are typical for director grants, aiming to incentivize long-term commitment and value creation.

Corporate Governance

Related Party Transactions

• The document details the grant of stock options to Brian O'Callaghan, a Director of Bolt Biotherapeutics, Inc., which constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The director receiving the options is incentivized to contribute to the company's success.

Next Steps

• Continued service of the Reporting Person to ensure vesting of the stock options.
• Potential future exercise of the stock options upon vesting and favorable market conditions.
• Monitoring of the company's next annual meeting date, as it impacts the vesting schedule.

Key Dates

Recommendation

Keywords

Bolt Biotherapeutics, BOLT, stock option, director, insider transaction, SEC Form 4, equity compensation, reverse stock split